Finance & Capital Markets

  1. Biotech M&A Trends With Allan Shaw 3/21/2022

    On this episode of the Business of Biotech, Allan Shaw waxes on his expectations for mergers, acquisitions, and collaborative partnership opportunities for new and emerging biotechs in 2022 and beyond. We tackle questions biotech leaders should be asking about intentionality, what's attractive to potential suitors, and why startups that aren't prepared to take a candidate to the finish line have already conceded a major factor in partnership or buyout negotiations. Don't miss Shaw's advice for startup success in a suddenly tumultuous market.

  2. Biotech Is Back With Allan Shaw 1/24/2024

    The Business of Biotech took a trip to San Francisco for the JP Morgan Healthcare Conference, that most target-richest of environments for those of us who like talking shop with biotech builders. The results of that trip will feed the next several weeks of Business of Biotech podcast programming, and we're kicking things off with everyone's favorite life sciences CFO, Allan Shaw.

  3. Building A Biotech Hub With Intellia Therapeutics' John Leonard, M.D. 1/13/2024

    We spend a lot of time talking with our guests about building biotech companies. That’s true of this episode too, but today we’re taking a step further with John Leonard, M.D., longtime CEO at Intellia Therapeutics.

  4. Dr. Randall Schatzman & The New Fundraising Norm 8/23/2020

    Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, discusses how his company has adjusted to pandemic-related disruption on the fundraising trail without missing a beat. He walks us through the remote-fundraising strategy that landed Bolt's recent $93.5 million Series C financing round, and how the company is moving towards an IPO in spite of market, civil, and political tumult. 

  5. Serial Success With Triumvira's Rob Williamson 3/10/2024

    Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Learn secrets to his serial success on this week's Business of Biotech podcast.

  6. Fed Funding: Creative Capital Generation With James Thomas Coates, Ph.D. 8/1/2022

    As biotech capital markets continue to restrict access to funding for emerging biopharmas, you might be surprised by how many federal dollars get left on the negotiating table. To that end, James Thomas Coates, Ph.D. and his team at Decisive Point have carved out a niche in the venture capital space.

  7. Biotech Cash Management With Allan Shaw 8/2/2023

    It’s been said that clinical trials are where emerging biotechs go to die. If the science doesn't kill quickly, poor cash management will slowly. On this week's episode of the Business of Biotech, our favored biotech finance management maven, Allan Shaw, offers pointed advice on stretching cash runways for the long run.

  8. Funding A Neurodegeneration Startup With Coya Therapeutics' Howard Berman 5/10/2023

    Like many of us, Howard Berman, Ph.D. has personal experience with the tragedy of cognitive decline. Neurodegenerative disorders are on the rise, and when one afflicted his father — a triple board-certified physician — he saw firsthand that they don't discriminate. Berman has dedicated his career to addressing neuro, autoimmune, and metabolic diseases, having founded Nicoya Health in 2020 and overseeing its merger with Coya Therapeutics the following year. The company came out of the gates this year fueled by an 11th-hour 2022 IPO, one of just a dozen on the year. Berman joined the Business of Biotech to share his strategy during a stingy stretch in biotech capital markets. 

  9. Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D. 8/21/2025

    On this week's episode, ex-handballer Vladimir Cmiljanovic, Ph.D., Founder and CEO at Swiss Rockets, talks about co-discovering bimiralisib with his sister Natasa Cmiljanovic, Ph.D. (and COO at Swiss Rockets), losing his company to a hostile takeover, buying the company back, and building out Swiss Rockets as an incubator with manufacturing capabilities and shared scientific expertise.

  10. A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D. 12/15/2024

    This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop AI-generated drugs. On this week's episode of the Business of Biotech, we're digging into the company's origin story and its place on the greater techbio landscape with one of the men bearing responsibility for Xaira's launch.